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Abstract
Introduction Epidural analgesia provides an important
synergistic method of pain control. In addition to
reducing perioperative opioid consumption, the
deliverance of analgesia into the epidural space,
effectively creating a sympathetic blockade, has
a multitude of additional potential benefits, from
decreasing the incidence of postoperative delirium to
reducing the development of persistent postsurgical
pain (PPSP). Prior studies have also identified a
correlation between the use of epidural analgesia
and improved oncological outcomes and survival. The
aim of this study is to evaluate the effect of epidural
analgesia in pancreatic operations on immediate
postoperative outcomes, the development of PPSP and
oncological outcomes in a prospective, single-blind,
randomised controlled trial.
Methods The Epidurals in Pancreatic Resection
Outcomes (E-PRO) study is a prospective, singlecentre, randomised controlled trial. 150 patients
undergoing either pancreaticoduodenectomy or distal
pancreatectomy will be randomised to receive an
epidural bupivacaine infusion following anaesthetic
induction followed by continued epidural bupivacaine
infusion postoperatively in addition to the institutional
standardised pain regimen of hydromorphone
patient-controlled analgesia (PCA), acetaminophen
and ketorolac (intervention group) or no epidural
infusion and only the standardised postoperative
pain regimen (control group). The primary outcome
was the postoperative opioid consumption, measured
in morphine or morphine-equivalents. Secondary
outcomes include patient-reported postoperative pain
numerical rating scores, trend and relative ratios of
serum inflammatory markers (interleukin (IL)-1β,
IL-6, tumour necrosis factor-α, IL-10), occurrence
of postoperative delirium, development of PPSP as
determined by quantitative sensory testing, and
disease-free and overall survival.
Ethics and dissemination The E-PRO trial has
been approved by the institutional review board.
Recruitment began in May 2016 and will continue until
the end of May 2018. Dissemination plans include
presentations at scientific conferences and scientific
publications.
Trial registration number NCT02681796.

Strengths and limitations of this study
►► Strengths of this study include its design as

a prospective randomised controlled trial and
the length of longitudinal follow-up provided
postoperatively.
►► Limitations include the single-institutional nature of
this study.

Introduction
Background and rationale
Epidural analgesia
The utilisation of regional analgesia as a
compliment to traditional pain management techniques has become an increasingly
common practice at many institutions. Placed
preoperatively, epidural analgesia provides an
important synergistic method of pain control
postoperatively. In addition to its usefulness as
a pain management adjunct, the deliverance
of analgesia into the epidural space, effectively creating a sympathetic blockade, has a
multitude of potential additional benefits.
Previous studies have examined the use
of epidurals in abdominal surgeries with a
small number of retrospective trials focusing
on the use of epidurals in pancreatic resections.1 While these retrospective studies
demonstrated an improvement in patient-reported pain scores postoperatively, objective
measures are still needed to quantify these
improvements in pain control.2 Prior studies
have also highlighted a correlation between
poor postoperative pain and the development
of persistent postsurgical pain (PPSP).3–5
As epidural analgesia creates a sympathetic
blockade, its intraoperative and postoperative use can mitigate the body’s inflammatory
response and reduce the activation of peripheral and central nervous system pathways
involved in the development of persistent pain
syndromes.6 Interleukin-1-beta (IL-1β), IL-6
and tumour necrosis factor-alpha (TNF-α)
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are three pro-inflammatory cytokines involved in the transition from acute pain states to chronic pain syndromes.7
IL-10 is an anti-inflammatory cytokine that helps modulate the body’s stress response. IL-1β, IL-6, TNF-α and
IL-10, and the relative balance of the pro-inflammatory
and anti-inflammatory response, have all been implicated
in nociceptive pathways and elevated levels have been
found in chronic pain processes.8 While our current
understanding of the complex modulation pathways of
pain is limited, circulating IL-6 has been demonstrated
in the upregulation of central and peripheral nociceptive receptors, thereby generating the perception of pain,
and potentially establishing the link between acute and
chronic pain.9 10 This is of particular importance in our
study population of patients with pancreatic diseases for
whom adequate pain control is a critical factor in maintaining good quality of life.11 12
In the immediate postoperative period, the use of
epidural analgesia can improve other measures of patient
recovery and healing, such as promoting gut motility
and reducing the incidence of postoperative delirium.
Along with reducing total opioid use, epidural analgesia
produces a sympathectomy, allowing for dominance
of the parasympathetic system, and further expediting
the return of bowel function.13–15 With delayed gastric
emptying as one of the most common complications and
reasons for readmission after pancreatic resections, this
valuable benefit of epidural analgesia requires further
investigation.16 17 Delirium is another common postoperative complication that is associated with poor patient
outcomes, including functional decline and death, and
an effective prophylactic treatment remains to be identified. Through the effects of decreased intraoperative
anaesthetic requirement and postoperative opioid use,
epidural analgesia may have a potential protective role
against postoperative delirium.
The effect of epidural analgesia in suppressing the
inflammatory cascade is of particular interest to the
field of oncology. In certain types of cancers, including
pancreatic, the oncogenic process generates an inflammatory environment that propagates the growth of
malignant lesions and continued inflammatory conditions have been implicated in metastatic disease.18–20
Pain can further exacerbate systemic inflammation.21 In
additional to mitigating postsurgical pain, the sympathectomy resulting from epidural analgesia also reduces
the body’s overall inflammatory conditions.22 23 This
attenuation of the heightened postoperative inflammatory state of the body may provide an additional means
of reducing progression of disease.
Pancreatic diseases
With improved detection and imaging modalities, the
incidence of pancreatic disease, and subsequently,
pancreatic operations, has increased.24–26 Pancreatic
resection continues to be the primary surgical treatment in the treatment of many benign and malignant
pancreatic diseases, with an estimated 4000 operations
2

performed annually in the USA.27 However, the mean
5-year survival for malignant pancreatic disease remains
the lowest of all cancers at 6%, with 70%–85% of patients
dying of systemic recurrence, not just local disease.28–30
While the search continues for earlier screening
methods, the development of adjunctive therapies to
surgical resection remains the most promising target of
efforts to improve outcomes in malignant diseases of the
pancreas. In particular, in recent years, a paradigm shift
has occurred in the study of pancreatic malignancies
where pancreatic cancer is viewed as a systemic disease,
even in early stages, requiring a systemic approach in
addition to regional disease control.31–34 In previous
studies, primarily in prostate and colorectal malignancies, the use of epidural analgesia has suggested a
correlation with improved oncological outcomes and
survival.35 36 Given the role between inflammation and
cancer development and recurrence, and the sympathetic blockade created by epidural analgesia, the
significance of epidural analgesia in improving oncological outcomes warrants continued investigation.
The aim of this study is to evaluate the effect of
epidural analgesia in pancreatic operations on immediate postoperative outcomes, the development of PPSP
and oncological outcomes in a prospective, single-blind,
randomised controlled trial.

Methods and analysis
Study design
The Epidurals in Pancreatic Resection Outcomes
(E-PRO) study is a prospective, single-centre, randomised
controlled trial. In total, 150 patients undergoing either
pancreaticoduodenectomy or distal pancreatectomy
will be randomised to receive an epidural infusion of
0.125% bupivacaine starting at 5 mL/hour (range of
5–8 mL/hour) following anaesthetic induction followed
by a standard epidural infusion of 0.1% bupivacaine at
4–6 mL/hour postoperatively in addition to the institutional standardised pain regimen of hydromorphone
patient-controlled analgesia (PCA), intravenous acetaminophen and ketorolac (intervention group) or no
epidural infusion and only the standardised postoperative pain regimen (control group). Follow-up information will be collected from the medical record for up to
2 years postoperatively. The study design is outlined in
figure 1.
Eligibility criteria
Patients 18 years old or older who are able to understand
and sign an institutional review board (IRB)-approved
informed consent form and who are undergoing either
pancreaticoduodenectomy or distal pancreatectomy will
be eligible for study inclusion. Patients will be excluded if
they fulfil any one of the following criteria: indication for
operative intervention being chronic pancreatitis, currently
on warfarin with an international normalised ratio (INR)
>1.4 or clopidogrel that cannot be discontinued 7 days prior
Pak LM, et al. BMJ Open 2018;8:e018787. doi:10.1136/bmjopen-2017-018787
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to surgery, most recent INR prior to surgery >1.4, most
recent platelet count prior to surgery <70 000/μL, chronic
opioid use as defined by use of >20 mg oxycodone, or equivalent, daily, history of pre-existing neuropathic pain conditions, known medical history of significant psychiatric or
cognitive impairment, or history of HIV, hepatitis B and/or
hepatitis C. Patients will be consented and enrolled during
a clinic or preoperative evaluation appointment.
Baseline assessment
Each study participant will be randomised into the control
group with standard of care pain management regiment or

Figure 1
scores.

the intervention group with the addition of epidural analgesia. Randomisation will occur via a randomised number
generation by the principal investigator (PI).
Patients will have the standard of care preoperative evaluation at the Barnes Jewish Hospital Center for Preoperative Assessment and Planning. Routine laboratory tests
including complete blood count, comprehensive metabolic panel and coagulation studies will be obtained and
reviewed.
In patients receiving chronic antiplatelet or anticoagulant medications, the following procedure will be

Study design. IL, interleukin; QST, quantitative sensory testing; TNF, tumour necrosis factor; VAS, visual analogue
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practised to minimise the risk of bleeding (per American Society of Regional Anesthesia and Pain Medicine
guidelines37).
Acetyl salicylic acid (aspirin) or other non-steroidal
anti-inflammatory drugs may be continued prior to
epidural catheter insertion. Clopidogrel use must be
discontinued 7 days before the procedure. The study
participant’s treating physician (eg, surgeon, cardiologist, neurologist) will be consulted prior to the discontinuation of clopidogrel. Participants receiving warfarin
will proceed with the following schedule: if INR <1.4,
subject may proceed with epidural catheter insertion.
If INR >1.4, the participant’s treating physician will be
consulted whether warfarin can be discontinued until
INR reaches <1.4 or the subject can be switched to
low-molecular weight heparin, which can be discontinued
36 hours before catheter insertion. INR and prothrombin
time (PTT) will be assessed on the day of epidural catheter insertion in all patients on anticoagulant (but not
antiplatelet) therapy.
Study participants will undergo a complete medical
history and physical examination, and the following baseline assessments:
1. Evaluation of hypersensitivity or dynamic mechanical allodynia to brush stimulation in the upper
abdomen.38
2. Quantitative sensory testing (QST) to assess warm and
cold detection thresholds, heat and cold pain thresholds, mechanical detection and pain thresholds, presence of wind-up (enhanced temporal summation) to
pinprick (online supplementary file 1).
3. Screening for psychological risk factors for acute and
chronic pain using Hospital Anxiety and Depression
Scale.39
4. Baseline assessment for delirium using the 3D-CAM
instrument.40
5. Baseline assessment of serum inflammatory markers
(IL-1β, IL-6, TNF-α, IL-10).
Interventions
Postoperatively, all patients will receive a standardised
pain regimen including a hydromorphone PCA (initial
settings of no bolus dose, 0.25 mg per demand dose,
minimal interval dose time of 10 min), acetaminophen
(1000 mg every 6 hours for 24 hours) and ketorolac
(15 mg every 6 hours for 72 hours) per surgeon’s preference. Study group patients will have an epidural bupivacaine infusion beginning in the operating room (OR).
An epidural infusion of 0.125% bupivacaine starting at
5 mL/hour (range of 5–8 mL/hour) will be started after
induction of anaesthesia. Epidural narcotic consisting of
fentanyl 50 μg will be administered with sterile precaution
by the anaesthesia provider before starting the epidural
infusion. Epidural boluses of 0.125% bupivacaine may be
administered as guided clinically. A phenylephrine infusion can be used to maintain adequate blood pressure
maintaining mean arterial pressures (MAP) >60 mm Hg.
The epidural infusion can be paused if vasopressor
4

requirements exceed 1 μg/kg/min of phenylephrine or
0.1 μg/kg/min of norepinephrine. The epidural infusion is to be paused if haemodynamics become unstable,
either due to excessive blood loss or MAP consistently
below 60 mm Hg. The epidural infusion can be resumed
when haemodynamics are stable.
The bupivacaine 0.125% epidural infusion is to be
discontinued in the OR at the end of surgery and a standard epidural infusion of 0.1% bupivacaine at 4–6 mL/
hour will be started in the post-anaesthesia care unit
(PACU). The epidural infusion is followed up by an Acute
Pain Service in the postoperative period that will titrate
the infusion based on the patients’ self-reported pain
scores and MAP values.
Outcomes
Primary outcomes
The primary study outcome is the postoperative
consumption of opioids (measured in morphine or
morphine-equivalents) in patients undergoing pancreatic resections in the control group compared with the
study group. Each subject’s morphine or morphine-equivalent consumption postoperatively will be assessed every
24 hours. All subjects will be assessed daily during their
postoperative inpatient admission by a trained member
of the Acute Pain Service who is blinded to the treatment
arm of the study.
Secondary outcomes
Secondary outcomes of the study include measures evaluated during the inpatient postoperative period as well
as during subsequent outpatient follow-up. Study team
members blinded to the treatment group of the patient
will assess all secondary outcomes. Patient recovery and
healing postoperatively will be evaluated using various
measures, such as visual analogue scores, intravenous
fluid requirements, anti-emetic doses and return of bowel
function. Serum inflammatory markers will be evaluated
serially, preoperatively on day of surgery, 3 hours after the
start of surgical incision in the OR, on postoperative day
2 (POD2) and at the initial postoperative visit 2–6 weeks
after surgery. Postoperative delirium assessments will be
performed when patients can be aroused sufficiently
in order to be assessed for delirium (Richmond Agitation-Sedation Scale > −4). Each patient will be assessed
for delirium on POD2 as postoperative delirium typically
first manifests 24–96 hours after surgery. For non-verbal
patients, the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) instrument will be used, and
for verbal patients, the 3D-CAM instrument will be used.40
As delirium is a fluctuating disorder and can be missed
with sporadic delirium assessments, a structured method
of chart review will be used to complement the clinical
assessments.
This combined approach (3D-CAM interview or
CAM-ICU plus chart review) increases the sensitivity
and retains specificity in detecting incident delirium.
The trial staff has undergone formal training in
Pak LM, et al. BMJ Open 2018;8:e018787. doi:10.1136/bmjopen-2017-018787
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clinical delirium assessment and on the chart review
methodology.
Patients will be seen for their initial postoperative weeks
at 2–6 weeks after hospital discharge and will undergo
repeat PPSP evaluation at that time.
Patients will continue to be followed in clinic for
2 years postoperatively with laboratory and radiological evaluation as deemed appropriate by the primary
surgeon. Patients will be followed for tumour recurrence
and overall survival. Data will be collected directly from
subject’s medical record; no study-specific procedures
will be implemented at follow-up visits.
Sample size
Sample size estimation was performed based on the study
primary outcome of postoperative opioid consumption.
Based on our prior experience, this estimation will be
based on the following assumptions41: expected morphine
consumption is 30 mg intraoperatively, 30 mg on postoperative day 1 (POD1), 20 mg on POD2 and 10 mg on
POD3. Therefore, expected total morphine consumption
in the first 72 hours is, on average, 80 mg. Then, assuming
that the SD of morphine consumption is 30 mg, that a
20 mg difference in morphine consumption between
groups is a clinically meaningful reduction of opioid use
and assuming normal distribution of morphine consumption in both patient groups, the proposed sample size
for a=0.05 and b=0.2 would be 37 patients per group (74
patients in total). However, we propose to increase the
sample size of the study to 150 total patients to account
for patients lost to follow-up, inability to complete the
scheduled pancreatic resection, data errors and other
unanticipated study problems.
Recruitment
Participants will be recruited primarily through the
Washington University Hepatobiliary-Pancreatic Surgery
clinics. Subjects will be given verbal (initially) and then
written descriptions of the study aims, procedures, risks
and benefits, and will be required to give written informed
consent. A member of the investigative team provides
all study descriptions, informed consent and answers all
questions. No deception is required for the purposes of
this study. All subjects will be aware of the randomisation
used in this study to either the control or intervention
group. Subjects are informed verbally and in writing that
participation is voluntary and they may refuse to participate and may withdraw from the study at any time without
penalty.
Allocation
Participants will be randomised in a 1:1 ratio into the
control group with standard of care pain management
regimen or the intervention group with the addition
of epidural analgesia. Randomisation will occur via
randomised number generation.
This is a single-blind study. Patients and the primary
investigative team will be aware of the randomisation.
Pak LM, et al. BMJ Open 2018;8:e018787. doi:10.1136/bmjopen-2017-018787

However, all study members performing data collection
will be blinded to the randomisation.
Data analysis and management
Data analysis for this study will focus on the comparison of patient outcomes (postoperative morphine/
morphine-equivalent consumption, measures of postoperative recovery, inflammatory markers, 3D-CAM/
CAM-ICU assessments, QST) between the intervention
and control study groups. Based on data distribution,
continuous variables will be compared between the two
groups using Student’s t-test or the Mann-Whitney U test
as appropriate. When appropriate, significance of findings will be adjusted for multiple comparisons using the
Bonferroni correction method.
The Center for Biomedical Informatics at Washington
University will be used as the central location for data
collection and management. Since 2008, Washington
University has hosted Research Electronic Data Capture
(REDCap), a secure, web-based application for building
and storing online research and clinical trial databases.
The REDCap servers are securely housed in an on-site
limited access data centre managed by the Center for
Biomedical Informatics at Washington University. All
web-based information transmission is encrypted, and all
data are stored on a private firewall-protected network.
All users are assigned individual user IDs, and passwords
and individual access is restricted on a role-specific
basis. REDCap was developed specifically around Health
Insurance Portability and Accountability Act (HIPAA)
guidelines and is also implemented and maintained in
accordance with institutional security guidelines.
Monitoring
The study team will monitor all study participants for
adverse events. The PI will report all unanticipated problems or adverse events, all conditions of non-compliance
and any new information that may affect the continued
or current enrolment of study participants to the IRB. All
events will be reported to the IRB within 10 working days
of the event or of notification of the PI of the event. The
death of a study participant must be reported to the IRB
within one working day of the event or of notification of
the PI of the event.
The specific monitoring plan for this investigation is
commensurate with the risks and the size and complexity
of the investigations planned. The potential risks are
attributable to performing insertion of the epidural
catheter and the use of bupivacaine for neuraxial analgesia. Based on these considerations, the monitoring
plan involves engaging a colleague from the Department
of Anesthesiology not involved in the study to serve in
a monitoring capacity. Based on the small size and relatively low-risk nature of the protocol, only a third person
(the colleague), rather than a full Data Safety Monitoring
Board, will be used. The colleague will be an anaesthesiologist knowledgeable in the risks associated with
nerve blocks and local anaesthetic administration. This
5
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individual will review the annual summary of adverse
events. In addition, this colleague will review all reports of
a serious adverse event or an unexpected adverse event.
Ethics and dissemination
Ethics approval and consent
The E-PRO trial was provided ethical approval by the
Washington University in St. Louis’s IRB which serves
Washington University and Barnes-Jewish Hospital. Study
recruitment and enrolment began in May 2016 and will
continue through the end of 2017. Potential study participants will be given verbal and then written descriptions of
the study aims, procedures, risks and benefits, and written
informed consent will be obtained for all participants. All
participants are informed verbally and in writing that
participation is voluntary and they may refuse to participate and may withdraw from the study at any time without
penalty.
Confidentiality
Only the investigators and research team will have access
to any protected health information of study participants
and any study data. All subjects will be assigned a study
ID number. All study data and samples will be coded with
the assigned study ID number. A key to the code linking
code numbers to patient names will be kept at a separate
location, under lock and key; this link will be destroyed at
the conclusion of this study. All data will be recorded by a
member of the research team and will be stored in a password-protected electronic database stored on the departmental network drive. Study data will not be entered into
participants’ medical records.
Dissemination
Dissemination plans include presentations at scientific
conferences and scientific publications.
Conclusions
This trial investigates a wide spectrum of potential benefits to patients undergoing pancreatic resection. During
the initial postoperative period, the use of epidural analgesia can aid in improving postoperative pain control,
decreasing opioid consumption, reducing the incidence
of delirium and expediting recovery. In addition to
improving immediate postsurgical pain control, epidural
analgesia may reduce the development of PPSP, which
can persist for weeks to years after surgery. Lastly, epidural
analgesia can help reduce the body’s stress response to
a major operation, which has been linked to malignant
progression and spread.
Based on this trial, we seek to establish the role of
epidural analgesia as part of the standard of care in future
patients undergoing pancreatic operations.
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